HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate fea...

Full description

Bibliographic Details
Main Authors:	Tatiana Kekeeva, Yulia Andreeva, Alexander Tanas, Alexey Kalinkin, Svetlana Khokhlova, Tatiana Tikhomirova, Alexandra Tyulyandina, Anatoly Popov, Maria Kuzmenko, Mikhail Volkonsky, Natalia Chernorubashkina, Valeria Saevets, Vadim Dmitriev, Valentina Nechushkina, Olga Vedrova, Sergei Andreev, Sergey Kutsev, Vladimir Strelnikov
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	International Journal of Molecular Sciences
Subjects:	homologous recombination deficiency <i>BRCA</i> mutation genomic instability score tumor purity pathological response
Online Access:	https://www.mdpi.com/1422-0067/24/13/10497

Similar Items

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
by: Loïck Galland, et al.
Published: (2023-02-01)

The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome
by: Luise D. Resch, et al.
Published: (2021-09-01)

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer
by: Florian Heitz, et al.
Published: (2023-01-01)

Characterization of BRCA Deficiency in Ovarian Cancer
by: Giovanna Barbero, et al.
Published: (2023-02-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
by: Gilda Magliacane, et al.
Published: (2022-12-01)

Hereditary Breast Cancer in Romania—Molecular Particularities and Genetic Counseling Challenges in an Eastern European Country
by: Andreea Cătană, et al.
Published: (2023-05-01)

<em>BRCA</em> Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies
by: Yen-Chien Lee, et al.
Published: (2021-08-01)

No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in <i>BRCA1</i> or <i>BRCA2</i> Mutation Families
by: Marion Imbert-Bouteille, et al.
Published: (2021-07-01)

Real-World Concordance between Germline and Tumour <i>BRCA1/2</i> Status in Epithelial Ovarian Cancer
by: Robert D. Morgan, et al.
Published: (2023-12-01)

Double Heterozygosity for Rare Deleterious Variants in the <i>BRCA1</i> and <i>BRCA2</i> Genes in a Hungarian Patient with Breast Cancer
by: László Madar, et al.
Published: (2023-10-01)

Tumour Versus Germline <i>BRCA</i> Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
by: Iolia Akaev, et al.
Published: (2021-03-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

Fanconi Anaemia, Childhood Cancer and the <i>BRCA</i> Genes
by: Emma R. Woodward, et al.
Published: (2021-09-01)

Predominance of <i>BRCA2</i> Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with <i>BRCA1</i> or <i>BRCA2</i> Mutation
by: Pascal Pujol, et al.
Published: (2022-07-01)

<i>BRCA1</i> and <i>BRCA2</i> Gene Mutations and Lung Cancer Sisk: A Meta-Analysis
by: Yen-Chien Lee, et al.
Published: (2020-04-01)

The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort
by: Aasem Abu Shtaya, et al.
Published: (2023-12-01)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
by: Michael Menzel, et al.
Published: (2023-09-01)

Disequilibrium between <i>BRCA1</i> and <i>BRCA2</i> Circular and Messenger RNAs Plays a Role in Breast Cancer
by: Corentin Levacher, et al.
Published: (2023-04-01)

<i>BRCA1</i> and Metastasis: Outcome of Defective DNA Repair
by: Rehna Krishnan, et al.
Published: (2021-12-01)

Is Reflex Germline <i>BRCA1/2</i> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?
by: Robert D. Morgan, et al.
Published: (2023-01-01)

<i>BRCA1/2</i> Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
by: Ettore Capoluongo, et al.
Published: (2019-10-01)

Analysis of Italian <i>BRCA1/2</i> Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy
by: Gisella Figlioli, et al.
Published: (2021-01-01)

Assessing Psychological Morbidity in Cancer-Unaffected <i>BRCA1/2</i> Pathogenic Variant Carriers: A Systematic Review
by: Anna Isselhard, et al.
Published: (2023-03-01)

An Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome
by: Diana Gonçalves, et al.
Published: (2022-07-01)

<i>BRCA1/2</i> Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome
by: Trong-Nhan N. Le, et al.
Published: (2022-01-01)

Laboratory Cross-Comparison and Ring Test Trial for Tumor <i>BRCA</i> Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
by: Zaida Garcia-Casado, et al.
Published: (2022-11-01)

Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
by: Ciara S. McNevin, et al.
Published: (2021-11-01)

Prognostic and Predictive Biomarkers in Familial Breast Cancer
by: Siddhartha Deb, et al.
Published: (2023-02-01)

Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family
by: Ieva Sadzevičienė, et al.
Published: (2020-03-01)

<i>BRCA</i> Mutations and Breast Cancer Prevention
by: Joanne Kotsopoulos
Published: (2018-12-01)

Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a <i>BRCA1/2</i> Mutation
by: Shuoying Qu, et al.
Published: (2023-12-01)

BRACNAC: A <i>BRCA1</i> and <i>BRCA2</i> Copy Number Alteration Caller from Next-Generation Sequencing Data
by: Andrey Kechin, et al.
Published: (2023-11-01)

Satisfaction and Quality of Life of Healthy and Unilateral Diseased <i>BRCA1/2</i> Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire
by: Natalie Herold, et al.
Published: (2022-07-01)

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
by: Eva-Maria Willing, et al.
Published: (2023-06-01)

How Does Dietary Intake Relate to Dispositional Optimism and Health-Related Quality of Life in Germline <i>BRCA1/2</i> Mutation Carriers?
by: Anne Esser, et al.
Published: (2023-03-01)

Prevalence of Germline <em>BRCA1/2</em> Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis
by: Antonio Cioffi, et al.
Published: (2023-01-01)

Mutations of <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
by: Matvey M. Tsyganov, et al.
Published: (2023-07-01)

Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
by: Lisa Kinget, et al.
Published: (2021-08-01)